Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which pump mode wins for exercise? new study tests SmartGuard vs temp target

NCT ID NCT06728423

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 14 people with type 1 diabetes who use the MiniMed 780G insulin pump. They will do a supervised strength training session twice, once with the pump in SmartGuard mode and once with a temporary target setting. The goal is to see which setting keeps blood sugar in a safe range and prevents low blood sugar during and after exercise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of type 1 diabetes ≥ 1 year ago * AHCL users (Minimed 780G) with integrated continuous glucose monitoring * Use of the device for at least the last 3 months * Physically active (PA≥1): At least one weekly physical exercise session in the last 6 months. Exclusion Criteria: * Pregnancy * Physical or mental inability to exercise * Contraindication to performing Valsalva maneuvers * History of osteoarticular disease that prevents exercise * History of tendinopathies that cause pain or limitation * History of coronary artery disease * Diabetic ketoacidosis or severe hypoglycemia in the last month * Evidence of autonomic failure (Unnoticed hypoglycemia given by Clarke 3 or more points Appendix 1) I am concerned because now that I am on a pump, this indication is common as support for the insulin pump. * Use of beta-blockers or glucocorticoids * Peripheral arterial disease * Severe proliferative diabetic retinopathy or non-proliferative diabetic retinopathy * Severe peripheral neuropathy * Stage 5 chronic kidney disease on renal replacement therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exercise are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario San Ignacio.

    Bogotá, Bogota D.C., 111021, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.